Strength from retail stocks, including Woolworths and Coles, helped offset weakness from the banking sector to lead the local share market higher last week.
The benchmark S&P/ASX 200 rose 0.45% to 5,906 points, while the broader All Ordinaries index gained 0.50% to finish last week at 5,971 points.
Standouts were the retail-related consumer discretionary and consumer staples sectors, which each rose more than 2%, while the financials and the mining-related materials sectors fell 0.74% and 0.92%, respectively.
Coles’ shares dipped at the end of last week after it announced a $146 million pre-tax provision as part of its plan to build automated distribution centres.
Investors reacted negatively to the outlay, however it was not enough to outweigh Coles’ gains earlier in the week off the back of strong wider market gains, according to CMC Markets’ chief analyst Michael McCarthy.
Canstar General Manager of Wealth Josh Callaghan said since Coles’ demerger from Wesfarmers late last year, the market was still trying to settle on what’s a fair value of the supermarket giant.
Coles and Woolworths were among the top five market value winners last week, with Coles’ adding about $574 million to its market value and Woolies’ market cap rising by about $738 million.
Healthcare giant CSL had the biggest market value gain last week, with its market cap growing by $1.3 billion.
ASX 200 Listed Companies – Top 5 Biggest Market Cap Gains and Losses (18/01/2019 to 25/01/2019) | |||||||||||
Biggest Gains | Biggest Losses | ||||||||||
Rank | Company | $ Change in Market Cap | Closing Share Price | % Change in Share Price | Rank | Company | $ Change in Market Cap | Closing Share Price | % Change in Share Price | ||
1 | CSL (CSL) | $1,345,285,518 | $199.16 | 1.5% | 1 | Resmed (RMD) | -$2,650,390,559 | $14.47 | -11.4% | ||
2 | Woolworths (WOW) | $737,753,497 | $30.52 | 1.9% | 2 | Commonwealth Bank (CBA) | -$1,221,465,260 | $72.54 | -0.9% | ||
3 | Aristocrat Leisure (ALL) | $664,085,916 | $24.60 | 4.4% | 3 | Challenger (CGF) | -$1,063,462,667 | $7.49 | -18.9% | ||
4 | Transurban (TCL) | $641,188,085 | $12.10 | 2.0% | 4 | AMP (AMP) | -$939,977,068 | $2.34 | -12.0% | ||
5 | Coles (COL) | $573,589,769 | $12.75 | 3.5% | 5 | Westpac (WBC) | -$930,844,176 | $25.88 | -1.0% | ||
Prepared by Canstar. Prices taken as of week to week close. |
Among the best share price performers, were electronics and furniture retailer Harvey Norman and Supercheap Auto owner Super Retail Group, with rises of more than 11% each.
Mr Callaghan said both retailers benefited from broker upgrades, which appealed to investors looking for value in the market.
“Super Retail Group hit a 52-week low in early January, so some analysts now see them as value,” he said.
Medical equipment company ResMed (RMD) was among the weakest performers on the market, with their shares falling by 11.4% to $14.47, following disappointing quarterly results.
A profit downgrade from financial firm AMP drove its shares down 12% to $2.34, slashing almost $940 million from its market value.
“News that AMP’s final dividend would be just four cents per share, down from more than 14 cents, saw a number of investors running for the door,” Mr Callaghan said.
He said he expected investors to be cautious with banking stocks in the lead up to the banking royal commission’s final report, which is set to be publicly released on Monday.
In other news, investment management giant Challenger released a weaker earnings’ outlook than the market had expected for the first half, which drove their share price down 18.9%.
ASX 200 Listed Companies – Top 5 Biggest Share Price Gains and Losses (18/01/2019 to 25/01/2019) | |||||||
Biggest Gains | Biggest Losses | ||||||
Rank | Company | Closing Share Price | % Change | Rank | Company | Closing Share Price | % Change |
1 | Harvey Norman (HVN) | $3.63 | 11.7% | 1 | Challenger (CGF) | $7.49 | -18.9% |
2 | Super Retail Group (SUL) | $7.49 | 11.6% | 2 | Northern Star (NST) | $8.05 | -15.0% |
3 | Costa Group (CGC) | $5.62 | 11.3% | 3 | AMP (AMP) | $2.34 | -12.0% |
4 | Estia Health (EHE) | $2.32 | 8.9% | 4 | Resmed (RMD) | $14.47 | -11.4% |
5 | Healius (HLS) | $2.94 | 8.9% | 5 | Sims Metal Management (SGM) | $9.98 | -8.9% |
Prepared by Canstar. Prices taken as of week to week close. |
Try our Online Share Trading comparison tool to instantly compare Canstar expert rated options.
This advice is general and has not taken into account your objectives, financial situation, or needs. It is not personal advice. Consider whether this advice is right for you, having regard to your own objectives, financial situation and needs. You may need financial advice from a suitably qualified adviser. For more information, read Canstar’s Financial Services and Credit Guide (FSCG) and our detailed disclosure. Canstar may receive a fee for referring you to a product provider – for further information, see how we get paid. Payment of fees for ads does not influence our Star Ratings or Awards.
Canstar is a comparison website, not a product issuer, so it’s important to check any product information directly with the provider. Consider the Product Disclosure Statement (PDS), Target Market Determination (TMD) and other applicable product documentation before making a decision to purchase, acquire, invest in or apply for a financial or credit product. Contact the product issuer directly for a copy of the PDS, TMD and other documentation.
Canstar is an information provider and in giving you product information Canstar is not making any suggestion or recommendation about a particular credit product or loan. If you decide to apply for a credit product or loan, you will deal directly with a credit provider, and not with Canstar. Rates and product information should be confirmed with the relevant credit provider. For more information, read the credit provider’s key facts sheet and other applicable loan documentation for that product. Read the Comparison Rate Warning.
All information about performance returns is historical. Past performance should not be relied upon as an indicator of future performance; unit prices and the value of your investment may fall or rise.
All information about performance returns is historical. Past performance should not be relied upon as an indicator of future performance; unit prices and the value of your investment may fall or rise.
Canstar is an information provider and in giving you product information Canstar is not making any suggestion or recommendation about a particular product. The information has been prepared without taking into account your individual investment objectives, financial circumstances or needs. Before you decide whether or not to acquire a particular financial product you should assess whether it is appropriate for you in the light of your own personal circumstances, having regard to your own objectives, financial situation and needs. You may wish to obtain financial advice from a suitably qualified adviser before making any decision to acquire a financial product. Please refer to the product disclosure statement (PDS) and Canstar’s Financial Services and Credit Guide (FSCG) for more information, and read our detailed disclosure, important notes and liability disclaimer.
Canstar may earn a fee for referrals from its website tables, and from Sponsorship or Promotion of certain products. Fees payable by product providers for referrals and Sponsorship or Promotion may vary between providers, website position, and revenue model. Sponsorship or Promotion fees may be higher than referral fees. Sponsored or Promotion products are clearly disclosed as such on website pages. They may appear in a number of areas of the website such as in comparison tables, on hub pages and in articles. Sponsored or Promotion products may be displayed in a fixed position in a table, regardless of the product's rating, price or other attributes. The table position of a Sponsored or Promoted product does not indicate any ranking or rating by Canstar. For more information please see How We Get Paid.
Any advice provided on this website is general and has not taken into account your objectives, financial situation or needs. Consider whether this advice is right for you. Consider the Product Disclosure Statement and Target Market Determination before making a purchase decision. Canstar provides an information service. It is not a credit provider, and in giving you information about credit products Canstar is not making any suggestion or recommendation to you about a particular credit product. Research provided by Canstar Research AFSL and Australian Credit Licence No. 437917. You must not reproduce, transmit, disseminate, sell, or publish information on this website without prior written permission from Canstar.